Skip to content

Systemic therapy

TL;DR

  • Metastatic LUSC is not one treatment state. The first decision integrates molecular results, PD-L1 tumour proportion score (TPS), performance status, disease tempo, symptoms, autoimmune and transplant history, organ function, and the need for rapid cytoreduction.
  • For fit patients without an actionable driver, pembrolizumab plus carboplatin and paclitaxel or nab-paclitaxel has direct, histology-specific phase III evidence across PD-L1 strata. High PD-L1 can support immunotherapy alone, but a high score does not guarantee response.
  • Dual-checkpoint regimens with limited or no chemotherapy are alternatives for selected patients. Cross-trial hazard ratios do not rank them, and toxicity profiles—not only median survival—often decide among them.
  • At progression, re-biopsy or plasma testing may expose a missed target, histological transformation, or a trial route. Docetaxel, docetaxel–ramucirumab, gemcitabine, and selected older agents remain useful; sequencing evidence after chemo-immunotherapy is much weaker than first-line evidence.
  • Brain, bone, and oligometastatic disease require coordinated local and systemic planning. Early specialist palliative care improves outcomes and is concurrent cancer therapy, not a final-line intervention.

Before choosing a regimen

The urgent question is not “which drug treats squamous lung cancer?” but “what clinical state needs treating?” A rapidly obstructing central tumour with hypoxaemia demands a different sequence from low-volume, asymptomatic metastatic disease even when both have the same PD-L1 result.

Domain Minimum information Treatment consequence
Diagnostic certainty Adequate morphology and immunophenotype; exclude metastasis from head/neck, skin, cervix, or other squamous primary Prevents treating the wrong disease and protects tissue for biomarkers
Extent Contrast CT, brain imaging where indicated, PET/CT or targeted staging; enumerate measurable and symptomatic sites Identifies curative, oligometastatic, and palliative pathways
Molecular Broad DNA/RNA profiling when tissue and access allow Rare actionable alterations are uncommon, not impossible; trial allocation often depends on them
Immune marker Assay and specimen-specific PD-L1 TPS Helps choose monotherapy versus combination; is not a binary biology
Fitness ECOG status, trajectory, frailty, weight loss, oxygen need, comorbidity Trial populations largely had ECOG 0–1; poor status from tumour may improve with response
Toxicity constraints Neuropathy, hearing, kidney and marrow reserve, pulmonary fibrosis, autoimmune disease, transplant Changes platinum, taxane, immune, and antiangiogenic suitability
Tempo Symptoms, doubling time, burden, threatened organ, prior response duration Favors rapid cytoreduction and early local intervention when needed
Goals Longevity, function, treatment time, tolerance of uncertainty, place of care Determines whether the mathematically longest regimen is personally best

The current ASCO living guideline is deliberately updated as evidence and authorizations change; local formulary and jurisdiction-specific approvals must therefore be checked at the point of care ([PMID 42190141](https://pubmed.ncbi.nlm.nih.gov/42190141/){target="_blank" rel="noopener"}).

First-line treatment without a targetable driver

Chemo-immunotherapy with direct squamous evidence

KEYNOTE-407 randomized 559 patients with untreated metastatic squamous NSCLC to carboplatin plus paclitaxel or nab-paclitaxel with pembrolizumab or placebo. Median overall survival (OS) was 15.9 versus 11.3 months (hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.49–0.85), and median progression-free survival (PFS) was 6.4 versus 4.8 months (HR 0.56, 95% CI 0.45–0.70) ([PMID 30280635](https://pubmed.ncbi.nlm.nih.gov/30280635/){target="_blank" rel="noopener"}). Grade ≥3 adverse events occurred in 69.8% versus 68.2%; discontinuation for adverse events was more frequent with pembrolizumab (13.3% vs 6.4%).

At five years, the OS HR was 0.71 (95% CI 0.59–0.85), PFS HR 0.62 (95% CI 0.52–0.74), and five-year OS 18.4% versus 9.7% ([PMID 36735893](https://pubmed.ncbi.nlm.nih.gov/36735893/){target="_blank" rel="noopener"}). Among the selected 55 patients completing 35 pembrolizumab cycles, response rate was 90.9% and three-year OS after completion was 69.5%; this survivor-enriched observation must not be projected onto all starters.

Patient-reported outcomes add a dimension hidden by grade tables. At week 18, global health/quality-of-life improved by 4.3 points with pembrolizumab combination and declined by 0.57 with chemotherapy alone; the between-group difference was 4.9 points (95% CI 1.4–8.3) ([PMID 31751163](https://pubmed.ncbi.nlm.nih.gov/31751163/){target="_blank" rel="noopener"}). The nominal analysis supports maintenance of quality of life but does not remove individual risks of neuropathy, fatigue, cytopenias, and immune toxicity.

When PD-L1 TPS is high

PD-1 monotherapy can avoid platinum and taxane toxicity in selected patients with high PD-L1 expression, low immediate threat, and no driver that should take precedence; KEYNOTE-024 established the strategy in PD-L1-high NSCLC ([PMID 27718847](https://pubmed.ncbi.nlm.nih.gov/27718847/){target="_blank" rel="noopener"}). EMPOWER-Lung 1 enrolled advanced NSCLC with PD-L1 at least 50%; in the prespecified PD-L1-high population, cemiplimab produced median OS not reached versus 14.2 months with chemotherapy (HR 0.57, 95% CI 0.42–0.77) and PFS 8.2 versus 5.7 months (HR 0.54, 95% CI 0.43–0.68) ([PMID 33581821](https://pubmed.ncbi.nlm.nih.gov/33581821/){target="_blank" rel="noopener"}). Never-smokers were excluded, an important transportability limit.

A high TPS is not a command to omit chemotherapy. Monotherapy avoids chemotherapy toxicity but can permit early progression in an intrinsically immune-resistant tumour. Combination therapy raises initial response probability and may be preferred for symptomatic, bulky, or fast-moving disease. Network meta-analysis can compare trial networks but cannot substitute for a randomized head-to-head choice in an individual ([PMID 38725635](https://pubmed.ncbi.nlm.nih.gov/38725635/){target="_blank" rel="noopener"}).

Dual-checkpoint strategies

Strategy Randomized evidence Practical trade-off
Nivolumab + ipilimumab In CheckMate 227, PD-L1 ≥1% median OS was 17.1 vs 14.9 months with chemotherapy; two-year OS 40.0% vs 32.8%. Benefit was also seen in PD-L1 <1% ([PMID 31562796](https://pubmed.ncbi.nlm.nih.gov/31562796/){target="_blank" rel="noopener"}) Avoids prolonged cytotoxic therapy but adds CTLA-4 immune toxicity and possible early progression
Nivolumab + ipilimumab + two chemotherapy cycles CheckMate 9LA improved OS versus four cycles of chemotherapy in all-comer NSCLC ([PMID 33476593](https://pubmed.ncbi.nlm.nih.gov/33476593/){target="_blank" rel="noopener"}) Attempts to bridge early cytoreduction with durable dual immunity; four-component complexity
Tremelimumab + durvalumab + chemotherapy POSEIDON OS HR 0.77 (95% CI 0.65–0.92), median 14.0 vs 11.7 months; PFS HR 0.72 Grade 3–4 treatment-related events 51.8% vs 44.4% with chemotherapy; durvalumab + chemotherapy without tremelimumab did not significantly improve OS ([PMID 36327426](https://pubmed.ncbi.nlm.nih.gov/36327426/){target="_blank" rel="noopener"})

These are NSCLC-wide results with histology-stratified enrollment, not direct comparisons against KEYNOTE-407 in LUSC. Treatment duration, steroid-requiring toxicity, baseline autoimmune risk, infusion burden, and access can outweigh small-looking cross-trial numerical differences.

Cytotoxic backbone decisions

Carboplatin plus paclitaxel or nab-paclitaxel is the best-studied contemporary squamous backbone; a phase III comparison reported a higher response rate with nab-paclitaxel in the squamous subgroup ([PMID 22547591](https://pubmed.ncbi.nlm.nih.gov/22547591/){target="_blank" rel="noopener"}). Cisplatin may be appropriate for selected fit patients in particular settings; carboplatin is often favored in metastatic disease for tolerability. Nab-paclitaxel avoids the conventional solvent and steroid premedication pattern but adds cost and neuropathy considerations. Gemcitabine plus platinum remains a non-immunotherapy option in jurisdictions or patients where checkpoint blockade is unsuitable.

Pemetrexed should not be used as the LUSC partner: in the pivotal cisplatin-doublet comparison, squamous median OS was 10.8 months with gemcitabine versus 9.4 months with pemetrexed ([PMID 18506025](https://pubmed.ncbi.nlm.nih.gov/18506025/){target="_blank" rel="noopener"}). Bevacizumab is generally avoided in squamous NSCLC because the phase III program excluded squamous tumours and clinically significant haemoptysis, and pulmonary haemorrhage accounted for five treatment-related deaths despite that selection ([PMID 17167137](https://pubmed.ncbi.nlm.nih.gov/17167137/){target="_blank" rel="noopener"}). Ramucirumab has different evidence and can be used with docetaxel after progression, but haemoptysis, vessel invasion, hypertension, thrombosis, and wound healing still require scrutiny.

Evaluating the first response

Finding Do not assume Better next step
Early enlargement on immunotherapy It is automatically pseudoprogression Assess symptoms, pace, new lesions, and confirm when clinically safe; pseudoprogression is uncommon
Cavitation It proves response Exclude infection, fistula, and bleeding risk; compare viable wall and total burden
Stable CT with clinical decline Treatment is working Search for embolus, infection, pneumonitis, airway obstruction, hypercalcaemia, and occult CNS progression
Oligoprogression All systemic control is lost Review local ablation and continued systemic therapy in a multidisciplinary setting
Complete radiographic response Cure is established Continue evidence-based surveillance; microscopic residual disease remains possible

Subsequent-line therapy

Evidence from the pre-immunotherapy era cannot answer every modern sequence. At progression, confirm that the patient truly progressed, characterize the pattern, review prior toxicity and depth/duration of benefit, repeat molecular testing when informative, and seek a biomarker-directed trial.

Checkpoint inhibitors when not previously received

CheckMate 017 directly enrolled previously treated squamous NSCLC. Nivolumab improved median OS to 9.2 versus 6.0 months with docetaxel (HR 0.59, 95% CI 0.44–0.79); one-year survival was 42% versus 24%, and grade 3–4 treatment-related events 7% versus 55% ([PMID 26028407](https://pubmed.ncbi.nlm.nih.gov/26028407/){target="_blank" rel="noopener"}). PD-L1 was neither prognostic nor predictive in that study.

KEYNOTE-010 in PD-L1-positive pretreated NSCLC showed median OS of 10.4 months with pembrolizumab 2 mg/kg, 12.7 months at 10 mg/kg, and 8.5 months with docetaxel; death HRs were 0.71 and 0.61, respectively ([PMID 26712084](https://pubmed.ncbi.nlm.nih.gov/26712084/){target="_blank" rel="noopener"}). Long-term follow-up documented durable outcomes and feasibility of protocol-defined retreatment in a highly selected group ([PMID 32078391](https://pubmed.ncbi.nlm.nih.gov/32078391/){target="_blank" rel="noopener"}). OAK similarly showed an OS advantage for atezolizumab over docetaxel in previously treated NSCLC across histologies ([PMID 27979383](https://pubmed.ncbi.nlm.nih.gov/27979383/){target="_blank" rel="noopener"}). These trials do not justify routine switching between PD-1/PD-L1 antibodies after true resistance to prior checkpoint blockade.

Chemotherapy and antiangiogenic therapy

REVEL randomized 1,253 previously platinum-treated patients to docetaxel plus ramucirumab or placebo. Median OS was 10.5 versus 9.1 months (HR 0.86, 95% CI 0.75–0.98), and PFS 4.5 versus 3.0 months (HR 0.76, 95% CI 0.68–0.86) ([PMID 24933332](https://pubmed.ncbi.nlm.nih.gov/24933332/){target="_blank" rel="noopener"}). Grade ≥3 neutropenia was common. The modest median gain must be weighed against bleeding risk, frailty, growth-factor use, and cumulative taxane toxicity.

Single-agent docetaxel or gemcitabine can be reasonable when combination toxicity is disproportionate. Afatinib modestly outperformed erlotinib in platinum-pretreated squamous carcinoma: median PFS 2.4 versus 1.9 months (HR 0.82) and OS 7.9 versus 6.8 months (HR 0.81) in LUX-Lung 8 ([PMID 26156651](https://pubmed.ncbi.nlm.nih.gov/26156651/){target="_blank" rel="noopener"}). This is not equivalent to finding an EGFR-sensitizing mutation and has a limited modern niche.

Antibody–drug conjugates must be read by histology. TROPION-Lung01 improved PFS overall with datopotamab deruxtecan versus docetaxel but not OS; in the squamous subgroup, median PFS was 2.8 versus 3.9 months (HR 1.41, 95% CI 0.95–2.08) and OS 7.6 versus 9.4 months (HR 1.32, 95% CI 0.91–1.92) ([PMID 39250535](https://pubmed.ncbi.nlm.nih.gov/39250535/){target="_blank" rel="noopener"}). An all-NSCLC headline can therefore conceal an unfavourable LUSC signal.

Special metastatic patterns

Brain metastases

Symptomatic lesions, mass effect, bleeding, seizures, or steroid dependence generally require urgent local-neurological planning. A phase II pembrolizumab study in selected asymptomatic NSCLC brain metastases 5–20 mm found intracranial responses in 11 of 37 PD-L1-positive patients (29.7%, 95% CI 15.9–47.0) and none in the PD-L1-negative/unevaluable cohort ([PMID 32251621](https://pubmed.ncbi.nlm.nih.gov/32251621/){target="_blank" rel="noopener"}). These selected data do not support deferring local therapy in an unstable patient.

Oligometastatic disease

In a small randomized phase II trial of NSCLC with no progression after initial systemic therapy and no more than three metastases, local consolidative therapy improved median PFS to 14.2 versus 4.4 months and median OS to 41.2 versus 17.0 months ([PMID 31067138](https://pubmed.ncbi.nlm.nih.gov/31067138/){target="_blank" rel="noopener"}). Only 49 patients were randomized and the trial closed early; multidisciplinary selection and newer systemic-era confirmation are essential.

Bone disease

Bone-modifying therapy reduces skeletal complications but requires dental review, renal/calcium assessment, vitamin supplementation as appropriate, and counselling about osteonecrosis of the jaw. An exploratory lung-cancer subgroup of a randomized trial found denosumab versus zoledronic acid median OS 9.5 versus 8.0 months in NSCLC (HR 0.78); in squamous disease, 8.6 versus 6.4 months (HR 0.68) ([PMID 23154554](https://pubmed.ncbi.nlm.nih.gov/23154554/){target="_blank" rel="noopener"}). Because this was exploratory and not multiplicity-protected, survival should not be the sole drug-selection claim. A systematic review found bisphosphonates reduce skeletal-related events but highlighted limitations in lung-specific evidence ([PMID 22956190](https://pubmed.ncbi.nlm.nih.gov/22956190/){target="_blank" rel="noopener"}).

Poor performance status and older adults

Chronological age is not a regimen. Frailty, cognition, falls, polypharmacy, nutrition, social support, renal function, and the cause of performance decline should be documented. Patients with ECOG 2–4, uncontrolled brain metastases, significant autoimmune disease, or organ transplant were underrepresented or excluded from pivotal trials; estimates above may not transfer. A reversible tumour-driven decline may justify active treatment, while a comorbidity-driven decline may magnify harm. Dose attenuation is a clinical decision, not evidence that an ineffective exposure becomes effective.

Early palliative care and stopping rules

Early palliative care alongside oncology improved 12-week FACT-L quality-of-life scores (98.0 vs 91.5), reduced depressive symptoms (16% vs 38%), reduced aggressive end-of-life care (33% vs 54%), and was associated with longer median survival (11.6 vs 8.9 months) in a randomized metastatic NSCLC trial ([PMID 20818875](https://pubmed.ncbi.nlm.nih.gov/20818875/){target="_blank" rel="noopener"}). Referral should occur for symptom burden, decision support, or caregiver strain—not only after anticancer options end.

At every assessment, define what would make the current regimen no longer worthwhile: confirmed progression without a useful local strategy, unacceptable toxicity, loss of a valued function, or a patient preference to stop. The next line should offer a plausible net benefit, not merely exist on a list.

Open questions

  1. Which post-chemo-immunotherapy sequence has the best LUSC-specific survival and patient-reported outcomes?
  2. Can KEAP1/NFE2L2, HLA state, or spatial immune phenotypes improve on PD-L1 for first-line selection?
  3. When does local ablation of oligoprogression meaningfully extend benefit from checkpoint blockade?
  4. How should treatment be adapted for ECOG 2–3 patients without confusing frailty with tumour-driven impairment?
  5. Which antibody–drug-conjugate payload and target can overcome the poor squamous signal seen with some all-NSCLC programs?

References

  1. Bazhenova L, Ismaila N, Durm G, Freeman-Daily J, Horinouchi H, MacVicar GR, et al. Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, 2026.3.1. J Clin Oncol. 2026;44(18):e101-e112. PMID 42190141
  2. Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040-2051. PMID 30280635
  3. Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, et al. Pembrolizumab Plus Chemotherapy in Squamous Non-Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study. J Clin Oncol. 2023;41(11):1999-2006. PMID 36735893
  4. Mazieres J, Kowalski D, Luft A, Vicente D, Tafreshi A, Gümüş M, et al. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020;38(3):271-280. PMID 31751163
  5. Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592-604. PMID 33581821
  6. Chen W, Liu H, Li Y, Xue W, Fan S, Sun J, et al. First-line immunotherapy efficacy in advanced squamous non-small cell lung cancer with PD-L1 expression ≥50%: a network meta-analysis of randomized controlled trials. Front Oncol. 2024;14:1365255. PMID 38725635
  7. Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim SW, Carcereny Costa E, et al. Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2019;381(21):2020-2031. PMID 31562796
  8. Paz-Ares L, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(2):198-211. PMID 33476593
  9. Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, et al. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: The Phase III POSEIDON Study. J Clin Oncol. 2023;41(6):1213-1227. PMID 36327426
  10. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373(2):123-35. PMID 26028407
  11. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-1550. PMID 26712084
  12. Herbst RS, Garon EB, Kim DW, Cho BC, Perez-Gracia JL, Han JY, et al. Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. J Clin Oncol. 2020;38(14):1580-1590. PMID 32078391
  13. Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255-265. PMID 27979383
  14. Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet. 2014;384(9944):665-73. PMID 24933332
  15. Soria JC, Felip E, Cobo M, Lu S, Syrigos K, Lee KH, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015;16(8):897-907. PMID 26156651
  16. Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, et al. Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study. J Clin Oncol. 2025;43(3):260-272. PMID 39250535
  17. Goldberg SB, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, et al. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21(5):655-663. PMID 32251621
  18. Gomez DR, Tang C, Zhang J, Blumenschein GR Jr, Hernandez M, Lee JJ, et al. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019;37(18):1558-1565. PMID 31067138
  19. Scagliotti GV, Hirsh V, Siena S, Henry DH, Woll PJ, Manegold C, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012;7(12):1823-1829. PMID 23154554
  20. Lopez-Olivo MA, Shah NA, Pratt G, Risser JM, Symanski E, Suarez-Almazor ME. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Support Care Cancer. 2012;20(11):2985-98. PMID 22956190
  21. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-42. PMID 20818875
  22. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055-62. PMID 22547591
  23. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543-51. PMID 18506025
  24. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-50. PMID 17167137
  25. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375(19):1823-1833. PMID 27718847